All In Biotech

Drug Trial Radar · NCT06920901

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma

A Phase 1b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of APG777 in Adults With Mild-to-Moderate Asthma

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

31

Actual

Start

Mar 27, 2025

Primary completion

Sep 17, 2026

Study completion Mar 2027

Sponsor

Lead sponsor
Apogee Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma. The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.

Conditions

  • Asthma

Interventions

  • APG777Drug

    APG777 subcutaneous injection

  • PlaceboDrug

    Matching placebo subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 52 weeks
  2. Number of Participants with Abnormal Laboratory FindingsTime frame: Up to 52 weeks
  3. Number of Participants with Abnormal Vital SignsTime frame: Up to 52 weeks
  4. Number of Participants with Abnormal Electrocardiograms (ECGs)Time frame: Up to 52 weeks
  5. Number of Participants with Abnormal Physical Examination FindingsTime frame: Up to 52 weeks

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigational Site

    La Jolla, California

  • Investigational Site

    Long Beach, California

  • Investigational Site

    San Jose, California

  • Investigational Site

    Torrance, California

  • Investigational Site

    Normal, Illinois

  • Investigational Site

    Kansas City, Missouri

  • Investigational Site

    Edmond, Oklahoma

  • Investigational Site

    Philadelphia, Pennsylvania

  • Investigational Site

    Pittsburgh, Pennsylvania

  • Investigational Site

    Manchester, United Kingdom

  • Investigational Site

    Bradford, West Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.